- Home
- MTVA vs RMCO Comparison
MTVA vs RMCO Comparison
Compare MTVA & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTVA
- RMCO
- Stock Information
- Founded
- MTVA 2014
- RMCO 2021
- Country
- MTVA United States
- RMCO United States
- Employees
- MTVA N/A
- RMCO N/A
- Industry
- MTVA
- RMCO Multi-Sector Companies
- Sector
- MTVA
- RMCO Miscellaneous
- Exchange
- MTVA NYSE
- RMCO Nasdaq
- Market Cap
- MTVA 14.3M
- RMCO 14.9M
- IPO Year
- MTVA N/A
- RMCO N/A
- Fundamental
- Price
- MTVA $0.66
- RMCO $1.25
- Analyst Decision
- MTVA Strong Buy
- RMCO
- Analyst Count
- MTVA 2
- RMCO 0
- Target Price
- MTVA $7.50
- RMCO N/A
- AVG Volume (30 Days)
- MTVA 133.9K
- RMCO 18.6K
- Earning Date
- MTVA 08-13-2025
- RMCO 08-14-2025
- Dividend Yield
- MTVA N/A
- RMCO N/A
- EPS Growth
- MTVA N/A
- RMCO N/A
- EPS
- MTVA N/A
- RMCO N/A
- Revenue
- MTVA N/A
- RMCO $1,568,212.00
- Revenue This Year
- MTVA N/A
- RMCO N/A
- Revenue Next Year
- MTVA N/A
- RMCO N/A
- P/E Ratio
- MTVA N/A
- RMCO N/A
- Revenue Growth
- MTVA N/A
- RMCO 204.08
- 52 Week Low
- MTVA $0.63
- RMCO $0.74
- 52 Week High
- MTVA $5.30
- RMCO $1.32
- Technical
- Relative Strength Index (RSI)
- MTVA N/A
- RMCO 62.27
- Support Level
- MTVA N/A
- RMCO $1.19
- Resistance Level
- MTVA N/A
- RMCO $1.30
- Average True Range (ATR)
- MTVA 0.00
- RMCO 0.06
- MACD
- MTVA 0.00
- RMCO 0.02
- Stochastic Oscillator
- MTVA 0.00
- RMCO 80.00
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.